Can I Take Ginseng with Tresiba (Insulin Degludec)?

What Is Tresiba and How Does It Work?

Tresiba is the brand name for insulin degludec, a long-acting basal insulin approved by the FDA for adults and pediatric patients (age 1 and older) with type 1 or type 2 diabetes [1]. After subcutaneous injection, degludec forms multi-hexamer chains that dissolve slowly at the injection site, producing a flat, peakless action profile with a duration exceeding 42 hours at steady state [2].

Pharmacokinetic Profile

Because degludec has an ultra-long half-life of approximately 25 hours, steady-state concentrations are not reached until after two to three days of daily dosing [2]. This delayed accumulation means that a dose reduction today will not fully lower circulating insulin levels until 48 to 72 hours later. That lag time matters when you are adding a glucose-lowering supplement: the combined effect builds over days, not hours.

Approved Doses

Clinical trials supporting FDA approval used degludec doses ranging from 0.1 to 1.6 units per kilogram per day [1]. The DEVOTE trial (N=7,637) compared degludec to insulin glargine U100 and found a 40% lower rate of severe nocturnal hypoglycemia with degludec (hazard ratio 0.60, 95% CI 0.48 to 0.76, P<0.001) [3]. That lower nocturnal hypoglycemia baseline is worth keeping in mind: adding a glucose-lowering supplement could partially offset that safety advantage.

What Is Ginseng and Why Does It Affect Blood Sugar?

Ginseng is a broad term covering several related botanical species. Panax ginseng (Asian or Korean ginseng) and Panax quinquefolius (American ginseng) are the two forms with the most human clinical data in glucose regulation [4]. Their active compounds, ginsenosides, appear to stimulate insulin secretion from pancreatic beta cells, improve peripheral glucose uptake via GLUT-4 translocation, and reduce hepatic glucose output [5].

Ginsenoside Mechanisms Relevant to Insulin Therapy

A 2019 systematic review published in Medicine (Baltimore) examined 16 randomized controlled trials of ginseng in type 2 diabetes and found that ginseng supplementation significantly reduced fasting blood glucose (mean difference: -0.84 mmol/L, 95% CI -1.28 to -0.40) and HbA1c (mean difference: -0.36%, 95% CI -0.68 to -0.04) compared with placebo [4]. These are not trivial reductions for someone whose basal insulin dose has already been titrated to a specific fasting glucose target.

American Ginseng vs. Asian Ginseng

A landmark controlled study by Vuksan et al. Published in Archives of Internal Medicine demonstrated that 3 g of American ginseng taken 40 minutes before a 25 g oral glucose challenge reduced the two-hour post-challenge glucose area under the curve by roughly 20% compared with placebo in both healthy volunteers and people with type 2 diabetes [6]. Asian ginseng appears to have similar but somewhat more variable effects across studies, likely because ginsenoside content varies widely by root age, preparation method, and standardization [4].

The Core Interaction: Pharmacodynamic Additive Glucose Lowering

The ginseng-Tresiba interaction is pharmacodynamic, meaning ginseng does not change how your body absorbs, distributes, metabolizes, or excretes insulin degludec. Instead, both substances independently lower blood glucose, and their effects simply add together [5].

Why This Matters More With Basal Insulin Than With Mealtime Insulin

Basal insulin like degludec works around the clock to suppress hepatic glucose production. Ginseng adds a layer of glucose lowering on top of that constant baseline suppression. With a rapid-acting insulin taken at a meal, you have a short action window and you can offset mild hypoglycemia by eating. With degludec's 42-hour action duration, there is no equivalent short window. Hypoglycemia triggered by ginseng can persist for hours.

Hypoglycemia: The Primary Safety Signal

The American Diabetes Association (ADA) 2024 Standards of Care define clinically significant hypoglycemia as a blood glucose below 54 mg/dL (3.0 mmol/L) [7]. Symptoms include tremor, diaphoresis, confusion, and, at lower levels, loss of consciousness. People with hypoglycemia unawareness, a condition affecting roughly 20 to 40% of people with long-standing type 1 diabetes, may not experience warning symptoms until glucose drops below 50 mg/dL [8].

Adding ginseng to a stable Tresiba regimen without dose adjustment or monitoring changes can push glucose into this danger zone, particularly overnight when basal insulin activity is ongoing and there is no food intake to buffer the drop.

Is There a Safe Dose of Ginseng With Tresiba?

No published randomized trial has established a formally safe ginseng dose for people on insulin degludec specifically. The studies that do exist used Panax quinquefolius doses of 1 to 3 g per day and showed meaningful glucose reductions at all tested doses [6]. Lower doses did not eliminate the glucose effect; they may have only moderated it.

Timing Does Not Eliminate the Risk

Some practitioners have asked whether taking ginseng at a different time of day from the Tresiba injection could reduce the interaction. Because degludec is active continuously over more than 42 hours and ginseng's ginsenosides have their own multi-hour activity window, there is no practical dose-separation strategy that removes the overlap. This differs from interactions involving shared hepatic enzymes, where taking drugs hours apart genuinely reduces peak co-exposure.

Standardization Problems in Commercial Products

Ginseng supplement quality varies substantially. A 2021 analysis found that ginsenoside content in commercially available ginseng products ranged from 0.6% to 9.2% by dry weight, despite similar label claims [9]. A person switching brands could inadvertently double their effective ginsenoside dose. For someone on a fixed Tresiba regimen, that switch could trigger hypoglycemia even if the prior brand was tolerated.

Anticoagulant Potentiation: A Secondary Concern

Beyond glucose lowering, ginseng has demonstrated antiplatelet activity in vitro and in small human studies. Ginsenoside Rg1 inhibits platelet-activating factor receptor binding, which reduces platelet aggregation [10]. For most people on Tresiba alone, this is not directly relevant to insulin therapy. It becomes relevant if you also take warfarin, aspirin, clopidogrel, or any novel oral anticoagulant. Concurrent use of ginseng with anticoagulants has been flagged in pharmacovigilance data for increased bleeding risk, though the magnitude in humans remains uncertain [10].

What the Guidelines Say

The ADA 2024 Standards of Care state: "Patients should be asked about the use of dietary supplements and herbal products at each clinical visit. Clinicians should inform patients that many supplements have hypoglycemic potential and may interact with antidiabetic medications" [7]. The Endocrine Society similarly recommends that clinicians perform a structured supplement review for all patients on insulin therapy, specifically because insulin has a narrow therapeutic index [11].

The Natural Medicines Database rates the ginseng-insulin combination as a "moderate" interaction, meaning the combination is not contraindicated but warrants monitoring and possible dose adjustment [5]. That moderate rating reflects the weight of evidence from multiple controlled trials showing meaningful glucose lowering.

What "Moderate Interaction" Means in Practice

A moderate interaction classification does not mean the combination is safe without action. It means the risk is real but manageable with appropriate clinical oversight. Specific management steps include:

• Telling your prescriber about the supplement before starting it.
• Increasing SMBG frequency to at least four times daily during the first two weeks of combined use.
• Reviewing your Tresiba dose target, since a lower fasting glucose target may be needed if ginseng is added.
• Having a documented hypoglycemia action plan, including glucagon availability for anyone with hypoglycemia unawareness.

Monitoring Protocol If You Are Already Taking Both

If you are already taking both Tresiba and a ginseng supplement without having discussed it with your prescriber, the first step is not to stop either abruptly. Stopping ginseng suddenly could cause a rebound increase in fasting glucose if your Tresiba dose was inadvertently titrated lower over time to compensate for ginseng's glucose-lowering effect. Contact your care team for a dose review.

Suggested Monitoring Steps

1. Check fasting glucose every morning for at least seven consecutive days and log the values.
2. Add a bedtime glucose check, since basal insulin is most active during overnight fasting hours.
3. Report any reading below 70 mg/dL (3.9 mmol/L) to your prescriber the same day.
4. If you experience nocturnal hypoglycemia symptoms, check glucose at 2:00 to 3:00 AM for three consecutive nights.

The DEVOTE trial (N=7,637) showed that severe hypoglycemia was associated with a three-fold higher risk of major adverse cardiovascular events in people with type 2 diabetes [3]. Minimizing hypoglycemia episodes is not just about comfort; it has measurable cardiovascular implications.

Continuous Glucose Monitoring Advantage

For people on basal insulin who use ginseng regularly, continuous glucose monitoring (CGM) provides a safety advantage over finger-stick SMBG alone. CGM devices such as the Dexterity G7 or FreeStyle Libre 3 provide trend arrows and low-glucose alarms that can catch overnight hypoglycemia before it becomes severe. The ADA 2024 Standards of Care recommend CGM for all adults with type 1 diabetes and for adults with type 2 diabetes who use insulin [7].

Special Populations With Higher Risk

Type 1 Diabetes

People with type 1 diabetes have no endogenous insulin secretion and no capacity to suppress basal insulin release in response to falling glucose. This makes them more vulnerable to additive glucose lowering from ginseng than people with type 2 diabetes, who may retain some compensatory glucagon and beta-cell responses.

Elderly Patients

Adults over age 65 have a higher prevalence of hypoglycemia unawareness and a greater risk of fall-related injury during hypoglycemic events. The ADA and American Geriatrics Society both recommend less aggressive glycemic targets for older adults on insulin, with HbA1c goals of 7.5 to 8.0% rather than below 7.0% [7]. Adding ginseng to a regimen already titrated to a tight target in this age group deserves particular scrutiny.

Renal Impairment

Patients with chronic kidney disease stage 3 or higher have reduced renal gluconeogenesis and slower insulin clearance, both of which already raise hypoglycemia risk. Ginseng's additive glucose lowering compounds this baseline vulnerability.

Talking to Your Prescriber: What to Bring to the Appointment

Many patients hesitate to disclose supplement use, either because they assume supplements are inherently safe or because they worry their prescriber will object. A 2017 survey published in JAMA Internal Medicine found that 34% of adults using prescription medications also used supplements, but fewer than 50% disclosed supplement use to their clinician [12]. That disclosure gap is where preventable drug-supplement interactions occur.

Bring the supplement bottle, including the brand name, ginsenoside percentage listed on the label, and your current daily dose. Your prescriber needs that information to gauge the likely magnitude of the glucose-lowering interaction. Also bring your recent glucose log or CGM download, since that data provides objective evidence of whether your control has shifted since starting ginseng.